Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Petosemtamab by Merus for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase III for Recurrent Head And Neck Squamous Cell Carcinoma....
Petosemtamab by Merus for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Petosemtamab by Merus for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase III for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Petosemtamab by Merus for Oropharyngeal Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III...
Petosemtamab by Merus for Hypopharyngeal Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Merus's Petosemtamab?
Petosemtamab is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....